Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
TransCode Therapeutics Inc. (RNAZ) had Consolidated Net Income/Loss of $-17.79M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-19.51M |
|
-- |
|
-- |
|
$17.75M |
|
$-17.75M |
|
$0.20M |
|
$-17.55M |
|
$-17.55M |
|
$-17.79M |
|
$-17.79M |
|
|
Consolidated Net Income/Loss |
$-17.79M |
$-17.79M |
|
$-17.75M |
|
$-17.73M |
|
0.92M |
|
0.92M |
|
$-21.28 |
|
$-21.28 |
|
| Balance Sheet Financials | |
$16.75M |
|
$0.35M |
|
$140.42M |
|
$157.16M |
|
$5.38M |
|
-- |
|
$150.53M |
|
$155.91M |
|
$1.25M |
|
$-138.79M |
|
$1.25M |
|
0.92M |
|
| Cash Flow Statement Financials | |
$-4.98M |
|
-- |
|
-- |
|
$17.81M |
|
$12.84M |
|
$-4.98M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-1421.32% |
|
12.81% |
|
-11.32% |
|
-1421.18% |
|
$1.36 |
|
$-5.43 |
|
$-5.43 |
|